Hassan G, Khalaf H, Mourad W
Department of Liver Transplantation and Hepatobiliary-Pancreatic Surgery, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Transplant Proc. 2007 May;39(4):1190-4. doi: 10.1016/j.transproceed.2007.04.009.
To report our experience with dermatological complications after both deceased donor liver transplantation (DDLT) and living-donor liver transplantation (LDLT).
Between April 2001 and November 2006, a total of 116 liver transplantation (LT) procedures were performed (73 DDLTs and 43 LDLTs) in 112 patients (4 re-transplants). Posttransplant dermatological problems were recorded.
Among 112 OLT recipients, 14 patients (12.5%) experienced dermatologic problems: epidermolysis bullosa acquisita in one patient, which was self-limiting; graft-versus-host-disease in one patient treated with high-dose steroids; Kaposi sarcoma in one patient treated with surgical excision and conversion to sirolimus-based immunosuppression; drug-induced cutaneous vasculitis with deep thigh ulcer formation treated by drug discontinuation and surgical excision of the ulcer; herpes zoster in one patient treated with intravenous antiviral therapy; herpes simplex in two patients treated with local antiviral cream; cyclosporine-induced gingival hyperplasia treated with conversion to FK506; cyclosporine-induced hypertrichosis treated with conversion to FK506; steroid-induced skin hyperpigmentation in one patient treated with steroid withdrawal; hypomagnesemia-induced hair loss treated with daily oral magnesium supplement; pressure-induced alopecia areata in two patients that was self-limiting; and finally, one patient with a pressure-induced heel ulcer that was treated conservatively. In 8 of 14 patients (57%) who suffered from dermatologic problems, the complication was primarily related to immunosuppressive drugs.
In our experience, dermatologic complications following LT are not uncommon and usually related to immunosuppressive therapy. Most complications could be prevented by optimizing immunosuppression. The majority of complications were easily managed by simple adjustment of immunosuppression.
报告我们在尸体供肝肝移植(DDLT)和活体供肝肝移植(LDLT)后皮肤并发症方面的经验。
2001年4月至2006年11月期间,共对112例患者(4例再次移植)实施了116例肝移植(LT)手术(73例DDLT和43例LDLT)。记录移植后的皮肤问题。
在112例OLT受者中,14例患者(12.5%)出现了皮肤问题:1例患者发生获得性大疱性表皮松解症,为自限性;1例患者发生移植物抗宿主病,接受大剂量类固醇治疗;1例患者发生卡波西肉瘤,接受手术切除并转换为基于西罗莫司的免疫抑制治疗;1例患者发生药物性皮肤血管炎并形成大腿深部溃疡,通过停药和溃疡手术切除进行治疗;1例患者发生带状疱疹,接受静脉抗病毒治疗;2例患者发生单纯疱疹,接受局部抗病毒乳膏治疗;1例患者因环孢素导致牙龈增生,通过转换为FK506进行治疗;1例患者因环孢素导致多毛症,通过转换为FK506进行治疗;1例患者因类固醇导致皮肤色素沉着过多,通过停用类固醇进行治疗;1例患者因低镁血症导致脱发,通过每日口服补充镁进行治疗;2例患者发生压力性斑秃,为自限性;最后,1例患者发生压力性足跟溃疡,接受保守治疗。在14例出现皮肤问题的患者中,8例(57%)的并发症主要与免疫抑制药物有关。
根据我们的经验,LT后的皮肤并发症并不少见,通常与免疫抑制治疗有关。通过优化免疫抑制可预防大多数并发症。大多数并发症通过简单调整免疫抑制即可轻松处理。